• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫组织化学检测肺腺癌患者的 EGFR 突变或 ALK 重排。

Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma.

机构信息

Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, CHU Nice, and Medical School, Nice Sophia University, Nice, France.

出版信息

Ann Oncol. 2012 Jul;23(7):1738-43. doi: 10.1093/annonc/mdr535. Epub 2011 Nov 18.

DOI:10.1093/annonc/mdr535
PMID:22100693
Abstract

BACKGROUND

Immunohistochemistry has been proposed as a specific and sensitive method to identify EGFR mutations or ALK rearrangements in lung tumours.

PATIENTS AND METHODS

We assessed EGFR and KRAS by direct sequencing in 154 patients with lung adenocarcinoma. ALK rearrangements were assayed by FISH and RT-PCR. Immunohistochemistry was carried out and evaluated closely following published methods using recommended monoclonal rabbit or mouse antibodies.

RESULTS

Thirteen of 36 exon 19 EGFR-mutated tumours (36%)-including 12 of 22 with p.Glu746_Ala750del (55%)-were positive with the 6B6 antibody that was raised against p.Glu746_Ala750del. One hundred eleven of 114 EGFR exon 19 wild-type tumours (97%) were negative with 6B6. Four of 21 exon 21 EGFR-mutated tumours (19%)-including 4 of 17 with p.Leu858Arg (24%)-were positive with the 43B2 antibody that was raised against p.Leu858Arg. One hundred twenty-two of 124 (98%) EGFR exon 21 wild-type tumours were negative with 43B2. Two of four ALK rearrangements-including two of three with ELM4-ALK fusion transcripts-were identified with the 5A4 antibody. Eleven of 13 tumours without ALK rearrangement (85%) were negative with 5A4.

CONCLUSIONS

Immunohistochemistry is a specific means for identification of EGFR mutations and ALK rearrangements. It suffers, however, from poor sensitivity.

摘要

背景

免疫组织化学已被提议作为一种特定且敏感的方法来鉴定肺癌中的 EGFR 突变或 ALK 重排。

患者和方法

我们在 154 例肺腺癌患者中通过直接测序评估了 EGFR 和 KRAS。ALK 重排在 FISH 和 RT-PCR 下进行检测。免疫组织化学按照已发表的方法进行,并使用推荐的单克隆兔或鼠抗体进行了密切评估。

结果

36 个外显子 19 EGFR 突变肿瘤中有 13 个(36%)——包括 22 个 p.Glu746_Ala750del 中有 12 个(55%)——用针对 p.Glu746_Ala750del 的 6B6 抗体呈阳性。114 个外显子 19 EGFR 野生型肿瘤中有 111 个(97%)用 6B6 呈阴性。21 个外显子 21 EGFR 突变肿瘤中有 4 个(19%)——包括 17 个 p.Leu858Arg 中有 4 个(24%)——用针对 p.Leu858Arg 的 43B2 抗体呈阳性。124 个外显子 21 EGFR 野生型肿瘤中有 122 个(98%)用 43B2 呈阴性。在 2 个 ALK 重排中——包括在 3 个具有 ELM4-ALK 融合转录本的重排中——用 5A4 抗体鉴定出 2 个。在 13 个没有 ALK 重排的肿瘤中,有 11 个(85%)用 5A4 呈阴性。

结论

免疫组织化学是鉴定 EGFR 突变和 ALK 重排的一种特定手段。然而,它的敏感性较差。

相似文献

1
Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma.免疫组织化学检测肺腺癌患者的 EGFR 突变或 ALK 重排。
Ann Oncol. 2012 Jul;23(7):1738-43. doi: 10.1093/annonc/mdr535. Epub 2011 Nov 18.
2
Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status.具有明确 EGFR 和 KRAS 状态的原发性肺腺癌中 ALK 重排的临床病理特征。
J Cancer Res Clin Oncol. 2014 Mar;140(3):453-60. doi: 10.1007/s00432-014-1584-8. Epub 2014 Jan 18.
3
The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.ALK重排以及KRAS和EGFR突变在原发性肺黏液腺癌中的临床病理意义
Tumour Biol. 2015 Aug;36(8):6417-24. doi: 10.1007/s13277-015-3331-4. Epub 2015 Mar 28.
4
Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.中国肺腺癌患者中表皮生长因子受体(EGFR)、棘皮动物微管相关蛋白样4-间变性淋巴瘤激酶(EML4-ALK)、 Kirsten大鼠肉瘤病毒癌基因(KRAS)和肝细胞生长因子受体(c-MET)突变分析
Exp Lung Res. 2013 Oct;39(8):328-35. doi: 10.3109/01902148.2013.819535. Epub 2013 Aug 6.
5
Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas.联合使用 ALK 免疫组织化学和 FISH 检测以优化 ALK 重排肺腺癌的检测。
J Thorac Oncol. 2013 Mar;8(3):322-8. doi: 10.1097/JTO.0b013e31827db604.
6
Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.突变谱与新的国际肺癌研究协会/美国胸科学会/欧洲呼吸学会分类为肺腺癌提供了额外的预后信息:一项对125例巴西患者的研究。
Oncology. 2015;89(3):175-86. doi: 10.1159/000376552. Epub 2015 Apr 1.
7
Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan.比较免疫组织化学(IHC)、荧光原位杂交(FISH)和 RT-PCR 方法在台湾 312 例非小细胞肺癌患者中检测 ALK 重排。
PLoS One. 2013 Aug 7;8(8):e70839. doi: 10.1371/journal.pone.0070839. eCollection 2013.
8
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.ROS1 重排对从不吸烟的肺腺癌患者临床结局的频率和影响。
Ann Oncol. 2013 Sep;24(9):2364-70. doi: 10.1093/annonc/mdt220. Epub 2013 Jun 19.
9
Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.从不吸烟的非小细胞肺癌患者中,携带 EGFR 或 KRAS 突变或 ALK 重排的患者具有独特的临床特征和结局。
Cancer. 2012 Feb 1;118(3):729-39. doi: 10.1002/cncr.26311. Epub 2011 Jun 30.
10
On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.ROS1 重排肺腺癌检测中检测算法的相关性。
Lung Cancer. 2014 Feb;83(2):168-73. doi: 10.1016/j.lungcan.2013.11.019. Epub 2013 Dec 1.

引用本文的文献

1
α‑Fetoprotein‑positive hepatoid adenocarcinoma of the stomach and a new classification: A case report.胃α-甲胎蛋白阳性肝样腺癌及新分类:病例报告
Oncol Lett. 2024 Oct 3;28(6):586. doi: 10.3892/ol.2024.14717. eCollection 2024 Dec.
2
Clinic-pathologic features and gene fusion pattern of ALK and ROS1 in non-small cell lung cancer show association with household coal combustion.非小细胞肺癌中ALK和ROS1的临床病理特征及基因融合模式显示与家用煤燃烧有关。
Transl Cancer Res. 2019 Sep;8(5):2164-2174. doi: 10.21037/tcr.2019.09.37.
3
Development of an immuno-wall device for the rapid and sensitive detection of EGFR mutations in tumor tissues resected from lung cancer patients.
免疫壁装置的开发用于快速灵敏地检测从肺癌患者切除的肿瘤组织中的 EGFR 突变。
PLoS One. 2020 Nov 16;15(11):e0241422. doi: 10.1371/journal.pone.0241422. eCollection 2020.
4
Anaplastic lymphoma kinase fusions: Roles in cancer and therapeutic perspectives.间变性淋巴瘤激酶融合:在癌症中的作用及治疗前景
Oncol Lett. 2019 Feb;17(2):2020-2030. doi: 10.3892/ol.2018.9856. Epub 2018 Dec 20.
5
Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How?在法国尼斯大学中心医院建立一个专门的肺癌生物样本库。原因及方式?
Cancers (Basel). 2018 Jun 29;10(7):220. doi: 10.3390/cancers10070220.
6
Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?免疫组织化学在肺癌患者治疗预测生物标志物中能占据一席之地吗?
Cancers (Basel). 2018 Mar 13;10(3):70. doi: 10.3390/cancers10030070.
7
Immunohistochemistry for predictive biomarkers in non-small cell lung cancer.非小细胞肺癌预测生物标志物的免疫组织化学
Transl Lung Cancer Res. 2017 Oct;6(5):570-587. doi: 10.21037/tlcr.2017.07.06.
8
Diagnostic accuracy of PCR for detecting ALK gene rearrangement in NSCLC patients: A systematic review and meta-analysis.聚合酶链反应(PCR)检测非小细胞肺癌(NSCLC)患者间变性淋巴瘤激酶(ALK)基因重排的诊断准确性:一项系统评价和荟萃分析。
Oncotarget. 2017 May 17;8(43):75400-75410. doi: 10.18632/oncotarget.17914. eCollection 2017 Sep 26.
9
ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice.间变性淋巴瘤激酶在非小细胞肺癌中的病理生物学、流行病学、肿瘤组织检测及日常实践中的算法诊断
Cancers (Basel). 2017 Aug 12;9(8):107. doi: 10.3390/cancers9080107.
10
Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.根据ALK融合变体的间变性淋巴瘤激酶(ALK)重排肺腺癌的临床结局
J Transl Med. 2016 Oct 19;14(1):296. doi: 10.1186/s12967-016-1061-z.